Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience
Philip Levy Ho(The University of Texas MD Anderson Cancer Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Colin P. Dinney(The University of Texas MD Anderson Cancer Center), Louis L. Pisters(The University of Texas MD Anderson Cancer Center), Jay B. Shah(The University of Texas MD Anderson Cancer Center), Stephen B. Williams(Cedars-Sinai Medical Center), Arlene O. Siefker‐Radtke(The University of Texas MD Anderson Cancer Center), Karen Tart(The University of Texas MD Anderson Cancer Center), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Jonathan Melquist(Baptist Cancer Center), Jeevitha Patil(The University of Texas MD Anderson Cancer Center), Scott E. Delacroix(National Cancer Institute), Sahil Parikh(The University of Texas MD Anderson Cancer Center), Daniel Willis(The University of Texas MD Anderson Cancer Center), Neema Navai(The University of Texas MD Anderson Cancer Center)
Cited by 72
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
|Journal of the American College of Cardiology|1996|1k
Acute Hyperglycemia Attenuates Endothelium-Dependent Vasodilation in Humans In Vivo
|Circulation|1998|804